The Food and Drug Administration today authorized Innovative Health Solutions Inc. to market an electrical nerve stimulator device to relieve opioid withdrawal symptoms when placed behind the patient’s ear. Previously approved for use in acupuncture, the NSS-2 Bridge device reduced symptoms for patients undergoing opioid withdrawal during a clinical study by at least 31% within 30 minutes, based on the clinical opiate withdrawal scale. Sixty-four of the 73 patients in the study transitioned to medication assisted therapy after five days using the device. “The FDA is committed to supporting the development of novel treatments, both drugs and devices, that can be used to address opioid dependence or addiction, as well as new, non-addictive treatments for pain that can serve as alternatives to opioids,” said FDA Commissioner Scott Gottlieb, M.D.

Related News Articles

Headline
Continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay infrastructure and…
Insights and Analysis
Also in this weekly roundup of nursing news: nurse leaders’ characteristics influence patient outcomes; a nurse helps a man who suffered a heart attack at the…
Headline
The Department of Health and Human Services Friday released guidance on its priorities for physician-focused payment models to help stakeholders who are…
Headline
U.S. overdose death rates linked to synthetic opioids increased more than 45 percent in 2017, likely driven by illicitly manufactured fentanyl, according to a…
Headline
The Health Resources and Services Administration recently launched a program to provide eligible health care clinicians with student loan repayment assistance…
Insights and Analysis
Also in this weekly roundup of health care news: how mandated access to at-home palliative care has made all the difference for some patients; and a town’s…